C
Charles Rauch
Researcher at Eli Lilly and Company
Publications - 3
Citations - 292
Charles Rauch is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Protein structure & Protein subunit. The author has an hindex of 2, co-authored 3 publications receiving 239 citations.
Papers
More filters
Journal ArticleDOI
Crystal structure of the human PRMT5:MEP50 complex
Stephen Antonysamy,Zahid Quyoom Bonday,Robert M. Campbell,Brandon Doyle,Zhanna Druzina,Tarun Gheyi,Bomie Han,Louis Nickolaus Jungheim,Yuewei Qian,Charles Rauch,Marijane Russell,J. Michael Sauder,S.R. Wasserman,Kenneth Weichert,Francis S. Willard,Aiping Zhang,S. Emtage +16 more
TL;DR: The crystal structure of human PRMT5 in complex with MEP50, bound to an S-adenosylmethionine analog and a peptide substrate derived from histone H4 is determined and the structure of the surprising hetero-octameric complex reveals the close interaction between the seven-bladed β-propeller MEP50 and the N-terminal domain ofPRMT5, and delineates the structural elements of substrate recognition.
Journal ArticleDOI
Cryo-electron microscopy structure of a human PRMT5:MEP50 complex.
TL;DR: Cryo-EM could be further utilized to understand PRMT5 interactions with other biologically important binding proteins and ligands, and shows good side chain definition and shows a well-resolved peak for a bound dehydrosinefungin inhibitor molecule.
Journal ArticleDOI
Structure-based, multi-targeted drug discovery approach to eicosanoid inhibition: Dual inhibitors of mPGES-1 and 5-lipoxygenase activating protein (FLAP).
Joseph D. Ho,Matthew R. Lee,Charles Rauch,Kristen Aznavour,Jonathan S. Park,John G. Luz,Stephen Antonysamy,Bradley Condon,Milan Maletic,Aiping Zhang,Michael J. Hickey,Norman Earle Hughes,Srinivasan Chandrasekhar,Ashley V. Sloan,Karen Gooding,Anita K. Harvey,Xiao-Peng Yu,Steven D. Kahl,Bryan H. Norman +18 more
TL;DR: These findings enhance the structural understanding of mPGES-1 and FLAP's unique ligand binding pockets and should accelerate the discovery of additional dual inhibitors for these two important integral membrane protein drug targets.